Research Hub

Live deal trackers & research reports

Reference tools for biotech and biopharma investors — updated regularly.

Live Trackers

Biotech M&A Tracker 2026

Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 39 deals. $106.7B tracked.

Last updated 30 May 2026

Biotech BD&L Tracker 2026

Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 58 deals. Up to US$18.5B largest package.

Last updated 30 May 2026

Biotech IPO Tracker 2026

Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 12 deals. ~$4.0B tracked.

Last updated 30 May 2026

Biotech Venture Funding Tracker 2026

VC and crossover rounds — company, stage, lead investors, therapeutic area, and what they are building. 87 deals. US$2.1B largest round.

Last updated 30 May 2026

Other Reports

29-May-26

Biotech Conference Calendar 2026

Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.

17-May-26

Most Active Biotech Investors 2026

Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.

08-Apr-26

Biotech M&A Q1 2026 Report

16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.

08-Jan-26

Biotech Funding Terms Glossary

Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.

07-Jan-26

2024 Biopharma M&A: Every $1B+ Deal

The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.